Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model - Wikidata - thesis-toulmin - TriplyDB

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

http://www.wikidata.org/entity/Q33608424

about

Sepsis-induced Cardiac Mitochondrial Damage and Potential Therapeutic Interventions in the Elderly Mitochondrial oxidative stress in aging and healthspan A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease Understanding and preventing mitochondrial oxidative damage Quality control systems in cardiac aging Quantification of mitochondrial morphology in neurites of dopaminergic neurons using multiple parameters Mitochondrial-targeted curcuminoids: a strategy to enhance bioavailability and anticancer efficacy of curcumin α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity Tempol, an intracellular antioxidant, inhibits tissue factor expression, attenuates dendritic cell function, and is partially protective in a murine model of cerebral malaria.Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease Mitochondrial ROS Induces Cardiac Inflammation via a Pathway through mtDNA Damage in a Pneumonia-Related Sepsis Model.Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.Mitochondrial Superoxide Contributes to Hippocampal Synaptic Dysfunction and Memory Deficits in Angelman Syndrome Model Mice Alterations in mitochondrial dynamics induced by tebufenpyrad and pyridaben in a dopaminergic neuronal cell culture model.The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease.Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration.P-glycoprotein (Mdr1a/1b) and breast cancer resistance protein (Bcrp) decrease the uptake of hydrophobic alkyl triphenylphosphonium cations by the brain.Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes.Cellular and animal models for mitochondrial complex I deficiency: a focus on the NDUFS4 subunit.The role of nanomedicine in cell based therapeutics in cancer and inflammation.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Mitochondrial dysfunction in central nervous system white matter disorders.Mitochondria-Targeted Antioxidants for the Treatment of Cardiovascular Disorders.Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease.Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy.Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.Mitochondria as a target for neuroprotection: implications for Alzheimer´s disease.Mitochondria and neurodegenerative diseases: the promising role of nanotechnology in targeted drug delivery.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Selective uncoupling of individual mitochondria within a cell using a mitochondria-targeted photoactivated protonophore.Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease.Ginsenoside Rb1 Prevents MPP(+)-Induced Apoptosis in PC12 Cells by Stimulating Estrogen Receptors with Consequent Activation of ERK1/2, Akt and Inhibition of SAPK/JNK, p38 MAPK.Specific inhibition of mitochondrial oxidative stress suppresses inflammation and improves cardiac function in a rat pneumonia-related sepsis model.The unintended mitochondrial uncoupling effects of the FDA-approved anti-helminth drug nitazoxanide mitigates experimental parkinsonism in mice.Tetrahydroxystilbene glucoside inhibits α-synuclein aggregation and apoptosis in A53T α-synuclein-transfected cells exposed to MPP.

P2860

Q26853544-A41F53BF-70A3-4C5D-BEC3-FAB48178663A Q27025099-250107BE-5BA8-480D-8B71-E4C21731E4D1 Q27307953-33250CEB-4E17-47C6-8B76-E9F58CDB56AF Q28080331-B1E87F8F-E43C-489D-B026-B2A6EEF1FAF0 Q28084341-92665163-0B40-4B96-A6EF-9464357A5B0F Q28272173-0DA57AAF-51CD-4EB1-AFCB-21A19A79529D Q28540774-50D51F04-8608-4952-9D64-AE8D5195B55B Q28572683-E16FA559-4AB9-4881-92FC-13C33D9FA369 Q30457536-8B79BCEF-A233-4153-BFA2-42258E16EB97 Q35829484-2EFFF56D-D8F5-41C8-A567-49FC1D6A4316 Q36137078-68E61515-5E6C-40B8-9E9B-4BB8E94E95F1 Q36369754-D491C86B-9408-40C7-802F-C52E30B789F9 Q36380931-CE68C913-9520-429D-99D5-60E955806678 Q36422034-F12AEE3C-18AB-446A-9451-ABCF74BA7E67 Q37048463-E0493495-1912-4A30-8940-AE84D2C9F184 Q37198050-2A0F1FF5-C15F-4823-9E0F-6181AC4860BD Q37304656-43C0A777-89AC-4231-96F8-C25A06BC5D65 Q37329938-53AF82FC-91DE-462D-9171-E8AC9C5A6B48 Q37504578-F881712D-E5A2-418D-87A2-9B5B3B67537D Q37653023-A5CEA14F-1170-46F0-83C2-57D1469A3D5D Q38078887-40D47DF9-F755-47CF-BBFD-033A2AC2AFFA Q38189402-E219EEAF-E7A5-4D7B-9F54-ACCA929F5A8D Q38202314-BEED3BD4-E247-4DA2-B31A-CBF0D0B767E0 Q38215315-BCDA4D4A-6685-48EC-ADAE-12B2D76A2F5E Q38678059-6BF9C061-1EDC-4244-B049-7DBD95AB4865 Q38692444-9B1FDF93-338D-4B50-9F6B-FDB518B7A828 Q38708951-4BF81809-AA7D-49F2-B4AA-6089931D6B70 Q38738244-3FF5D188-DF2D-4355-9502-06C218968BC0 Q38855994-6D5CFFB2-A747-4EAB-AC85-6BD5B2A12B73 Q38883083-B4CA150D-356D-4A8D-8139-DC02E5D66058 Q38910964-24F20D8D-3671-4E6A-B1B0-23290E297076 Q39199926-12FFBBB4-6342-4AE1-B74E-3B0E84D21CA3 Q39329410-AF326097-0D2B-4709-9452-896918F24BDA Q39400621-545671E8-A36F-40B7-8FB3-C9D9A8A321B3 Q40485681-F7AC00A7-7607-4A02-A928-D180F01AD87E Q41349377-C5709D80-DA00-48B8-83AE-0CEF670F61F1 Q42252658-7F4A6D8B-2439-466E-B6CD-F074BEA94947 Q44290150-E9A8E188-CA05-44ED-9223-E80C289EF148 Q46322674-616EDD24-B548-41DB-9AA4-17238DBEC168 Q46419738-04F281BA-020B-42CA-8BD0-5F1952817004

P2860

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

http://www.wikidata.org/entity/Q33608424

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@ast

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@en

type

label

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@ast

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@en

prefLabel

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@ast

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@en

P1433

Q33608424-93839B52-88A6-44B8-B41A-1F81F944884E

P1476

Q33608424-5598C433-B2DB-4818-A51A-9BB4DC8DEA02

P2093

Q33608424-13FB5F47-3E2E-4CB9-8255-3FB80EECF39C

Q33608424-2C2D11BA-746A-4B86-B218-921C8B0C33A5

Q33608424-5A9D0895-A46A-4098-8B2E-46CC121CD2A3

Q33608424-902DA1E3-703C-448E-922D-9A358D3B7946

Q33608424-980047A3-84ED-46F1-B852-9DF3FE0AF4A5

Q33608424-B78B51EC-4569-46EC-BE0C-3A69C5B6E2A0

Q33608424-BFC63AA1-4732-4DBF-803E-FF8CF4DC30D4

Q33608424-C00EDF7E-EE0F-4A73-BECB-37CF8867A01F

Q33608424-CAE949F6-F9F9-4151-BE6A-28EFF44D586B

P2860

Q33608424-0198CBF1-5DA9-4F37-9D5B-227B52C6ADDE

Q33608424-04F7208B-E5D3-4CB7-B3A8-AABDE3C128C4

Q33608424-0A4B5349-6884-4CE8-A45B-CF63AD5CAC52

Q33608424-0BD1524C-4BBA-4FEF-A83B-B94A85E5B4FF

Q33608424-11AAFA47-91D0-4B27-98E4-5895AE99AC48

Q33608424-11FB584F-6965-4B86-8F67-CECA973602D8

Q33608424-18EE0471-C1A6-4346-81D4-FA9AEE4F0EF4

Q33608424-20926DBF-8BF2-42C2-A239-CA46799638D3

Q33608424-20FC444C-CF6B-4E65-AE3C-5DE726595DD6

Q33608424-262FA681-0EB2-42AA-BE0B-FFD929F7AE6F

P304

Q33608424-F7EBD634-483B-4297-8E54-3B8C28F0E7C3

P31

Q33608424-C186E84E-E57C-48D4-BF6A-1FE276970E88

P356

Q33608424-4972F361-2688-49FE-AD72-D7E8F392C09B

P433

Q33608424-5A7E8064-4825-4909-842E-6ECB7AE9DD41

P478

Q33608424-9E21697F-F534-4C41-9F4E-B362F2685EFF

P577

Q33608424-BC24777B-8D36-4560-A6D6-6CF521457EED

P5875

Q33608424-E798B3D1-411A-455A-962B-6450B3C1AF2F

P698

Q33608424-730FE82F-6C41-4036-8C97-75859B9B8549

P921

Q33608424-9F4B37F5-5CFC-41E6-A3F9-FF056EA1A420

Q33608424-CC200438-2023-4990-84E2-3300521F8D22

P932

Q33608424-08A0A8A0-8142-458B-AF1D-74738A6007FE

P356

J.FREERADBIOMED.2010.08.028

P1433

Free Radical Biology and Medicine

P1476

Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model

@en

P2093

Anamitra Ghosh

http://www.w3.org/2001/XMLSchema#string

Anumantha Kanthasamy

http://www.w3.org/2001/XMLSchema#string

Arthi Kanthasamy

http://www.w3.org/2001/XMLSchema#string

Balaraman Kalyanaraman

http://www.w3.org/2001/XMLSchema#string

Cecilia J Hillard

http://www.w3.org/2001/XMLSchema#string

Joy Joseph

http://www.w3.org/2001/XMLSchema#string

Karunakaran Chandran

http://www.w3.org/2001/XMLSchema#string

Shasi V Kalivendi

http://www.w3.org/2001/XMLSchema#string

William E Antholine

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease

Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Chronic Parkinsonism secondary to intravenous injection of meperidine analogues

Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease

Significance of some previously unrecognized apomorphies in the nasal region of Homo neanderthalensis

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Molecular pathways of neurodegeneration in Parkinson's disease

Selective targeting of an antioxidant to mitochondria.

P304

1674-1684

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.FREERADBIOMED.2010.08.028

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230778730

http://www.w3.org/2001/XMLSchema#string

P698

20828611

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

4020411

http://www.w3.org/2001/XMLSchema#string